Skip to main content
Yiwen Lu on Muck Rack

Yiwen Lu

New York
As seen in: MSN, MSN Brasil, The New York Times, Color Research & Application, Estadão, Nature, The Washington Post, Wiley Online Library, Yahoo Canada, Yahoo News and
taking a break from mental health to focus on my social media • signal: ywlu.26
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yiwen

Contact Yiwen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

MOSAiC: Multi-site One-Shot Aggregation of Compressed Risk Functions

|
By Yong Chen, Yiwen Lu, Jing-Mei Qiu
| Taylor & Francis Online
?Mathematical formulae have been encoded as MathML and are displayed in this HTML version using MathJax in order to improve their display. Uncheck the box to turn MathJax off. This feature requires Javascript. Click on a formula to zoom.
Open in Who Shared Issue with article?

Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us

|
By Maxwell Salvatore, Bingyu Zhang, Huilin Tang, Yiwen Lu, Dazheng Zhang, Ting Zhou, Yuan Lu, Anastassia Amaro, Marylyn D. Ritchie, Yong Chen
| Nature Verified
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes (T2D) and weight management, yet their real-world health impacts remain understudied.
Open in Who Shared Issue with article?

Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine

|
By Holly Janes, Youyi Fong, Ying Huang, David Benkeser, Elizabeth Kelly, Ian Hirsch, Ann Marie Stanley, Tonya L Villafana, Christos Petropoulos, Andrew Leith, Bill Webb, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Nima Hejazi, April K. Randhawa, Michele Andrasik, James G. Kublin, Margaret Brewinski Isaacs, Tina Tong, Merlin L. Robb, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Ann R Falsey, Magdalena E. Sobieszczyk, Richard A. Koup, Peter Gilbert, Deanne Haugaard, Lars W. P. van der Laan, Mamodikoe Makhene
| Nature Verified
Abstract In the phase 3 AZD1222 COVID-19 vaccine trial, anti-Spike (vaccine-matched and Delta) binding IgG antibody concentration and neutralizing antibody (nAb) titer (vaccine-matched+D614G and Delta), measured four weeks post-dose two (D57), were assessed as correlates of risk of severe COVID-19 and Delta COVID-19 over ~4 to ~13 months (severe) or ~11 months (Delta) post-D57.
Open in Who Shared Issue with article?
See all 501 licensed articles (579 Total)